Hanmi Science (KRX:008930) secured a contract for the supply of Daparon tablets/Daparon Duo extended-release tablets with Mexico's Laboratorios Sanfer, according to a Wednesday filing with the Korea Exchange.
The contract, valued at 65.8 billion won, is valid till Jan. 26, 2036.
Shares of Hanmi Science rose over 1% in recent trade.